Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Versus Capecitabine as First-Line Chemotherapy in Elderly/Poor PS Patients With Gastric Cancer
NCT00580359Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2007
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, capecitabine in gastric cancer (GC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tegafurcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00580359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580359.